Menlo Park, United States
Orca Bio, founded in 2016, is a promising late-stage biotechnology company based in the United States, innovating in the realms of Health Care and Pharmaceutical industries. Their mission, encapsulated by the slogan, "Transforming allogeneic cell therapy for patients with cancer and autoimmune diseases," is focused on creating high-precision cell therapies that aim to replace diseased blood and immune systems with healthy counterparts.
The company stands out with its advanced manufacturing platform, which harnesses single-cell precision to develop proprietary products with revolutionary potential in allogeneic cell therapy. Backed by an accomplished team of scientists, engineers, and clinicians, Orca Bio is positioned to push the boundaries of treatment by delivering the promise of a cure without compromise.
In terms of investment milestones, Orca Bio secured a $192.00M Series D funding on June 17, 2020, attracting prominent investors such as Lightspeed Venture Partners, 8VC, Blue Chip Venture Company, Mubadala, IMRF, ND Capital, Dream Variation Ventures, DCVC Bio, Kaiser Family Foundation, and Kaiser Permanente. This robust capital backing highlights investor confidence in the company's innovative approach and potential to impact the healthcare sector significantly.
